Logo.png
BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease
12 juin 2023 07h00 HE | BioRestorative Therapies, Inc
--Clinical data expected to be reviewed by independent data safety monitoring board (DSMB) as to initial safety dosing profile of BRTX-100--  MELVILLE, N.Y., June 12, 2023 (GLOBE NEWSWIRE) --...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Achievement of Target Patient Dosing in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Hemophilia B
26 mars 2020 07h00 HE | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, March 26, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet...